Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MBTPS1 | Q14703 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993873 | 0.92 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3DRD2NOS2 | |
| SCHEMBL4486350 | 0.86 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3NOS2KCNH2 | |
| SCHEMBL4484262 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3NOS2KCNH2 | |
| SCHEMBL4489240 | 0.84 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3NOS2KCNH2 | |
| SCHEMBL20871388 | 0.83 | DRD2 (0.50) | SLC6A2SLC6A4SLC6A3DRD2KMT2A | |
| SCHEMBL4483536 | 0.82 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL4498305 | 0.81 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20871142 | 0.79 | DRD2 (0.49) | SLC6A2SLC6A4SLC6A3DRD2KMT2A | |
| SCHEMBL4488758 | 0.79 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4486367 | 0.79 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3NOS2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | claimed |
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | SLC6A2 1/4885SLC6A4 5/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.